Ocular manifestations and complications of Stevens-Johnson syndrome and toxic epidermal necrolysis: An Asian series

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 62, Issue 5, 2007, Pages 527-531

  Yip, L W ^a   Thong, B Y ^a   Lim, J ^a   Tan, A W ^b   Wong, H B ^c   Handa, S ^a   Heng, W J ^a  

^a TAN TOCK SENG HOSPITAL   (Singapore)

^b NATIONAL SKIN CENTRE   (Singapore)

^c Clinical Trials and Epidemiology Research Unit   (Singapore)

Author keywords

Drug eruptions; Eye manifestations; Risk factors; Stevens Johnson syndrome; Toxic epidermal necrolysis

Indexed keywords

ANTIBIOTIC AGENT;

ADULT; AGED; ASIA; DEMOGRAPHY; DISEASE SEVERITY; DRY EYE; EYE CARE; EYE DISEASE; EYE INJURY; EYELASH; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PRIORITY JOURNAL; REVIEW; RISK FACTOR; STEVENS JOHNSON SYNDROME; THROMBOCYTOPENIA; TOXIC EPIDERMAL NECROLYSIS;

ASIA; EPIDERMAL NECROLYSIS, TOXIC; EYE DISEASES; FEMALE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; STEVENS-JOHNSON SYNDROME;

EID: 34247239254     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/j.1398-9995.2006.01295.x     Document Type: Review

References (16)

1. Thong BY, Leong KP, Tang CY, Chng HH. Drug allergy in a general hospital: results of a novel prospective inpatient reporting system. Ann Allergy Asthma Immunol 2003;90:342-347.
2. Arstikaitis MJ. Ocular aftermath of Stevens-Johnson syndrome. Arch Ophthalmol 1973;90:376-379.
3. Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000;115:149-153.
4. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993;129:92-96.
5. Power WJ, Ghoraishi M, Merayo-Lloves J, Neves RA, Foster CS. Analysis of the acute ophthalmic manifestations of the erythema multiforme/Stevens-Johnson syndrome/toxic epidermal necrolysis disease spectrum. Ophthalmology 1995;102:1669-1676.
6. Baudouin C. Allergic reaction to topical eyedrops. Curr Opin Allergy Clin Immunol 2005;5:459-463.
7. Furrer P, Mayer JM, Gurny R. Ocular tolerance of preservatives and alternatives. Eur J Pharm Biopharm 2002;53:263-280.
8. Geerling G, Daniels JT, Dart JK, Cree IA, Khaw PT. Toxicity of natural tear substitutes in a fully defined culture model of human corneal epithelial cells. Invest Ophthalmol Vis Sci 2001;42:948-956.
9. Puangsricharern V, Tseng SC. Cytologic evidence of corneal diseases with limbal stem cell deficiency. Ophthalmology 1995;102:1476-1485.
10. Wilson SE, Li Q, Weng J, Barry-Lane PA, Jester JV, Liang Q et al. The Fas-Fas ligand system and other modulators of apoptosis in the cornea. Invest Ophthalmol Vis Sci 1996;37:1582-1592.
11. Revuz J, Penso D, Roujeau JC, Guillaume JC, Payne CR, Wechster J et al. Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients. Arch Dermatol 1987;123:1160-1165.
12. Posadas SJ, Padial A, Torres MJ, Mayorga C, Leyva L, Sanchez E et al. Delayed reactions to drugs show levels of perforin, granzyme B, and Fas-L to be related to disease severity. J Allergy Clin Immunol 2002;109:155-161.
13. Kawasaki S, Nishida K, Sotozono C, Quantock AJ, Kinoshita S. Conjunctival inflammation in the chronic phase of Stevens-Johnson syndrome. Br J Ophthalmol 2000;84:1191-1193.
14. Foster CS, Fong LP, Azar D, Kenyon KR. Episodic conjunctival inflammation after Stevens-Johnson syndrome. Ophthalmology 1988;95:453-462.
15. Paquet P, Jacob E, Damas P, Pirson J, Pierard G. Analytical quantification of the inflammatory cell infiltrate and CD95R expression during treatment of drug-induced toxic epidermal necrolysis. Arch Dermatol Res 2005;297:266-273.
16. Yip LW, Thong BY, Tan AW, Khin LW, Chng HH, Heng WJ. High-dose intravenous immunoglobulin in the treatment of toxic epidermal necrolysis: a study of ocular benefits. Eye 2005;19:846-853.